Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Payables (2023 - 2025)

Historic Payables for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $6.1 million.

  • Immunome's Payables rose 7473.0% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 7473.0%. This contributed to the annual value of $14.2 million for FY2024, which is 32854.12% up from last year.
  • Immunome's Payables amounted to $6.1 million in Q3 2025, which was up 7473.0% from $4.7 million recorded in Q2 2025.
  • Immunome's Payables' 5-year high stood at $14.2 million during Q4 2024, with a 5-year trough of $2.8 million in Q3 2023.
  • Moreover, its 3-year median value for Payables was $4.7 million (2025), whereas its average is $5.9 million.
  • Per our database at Business Quant, Immunome's Payables soared by 32854.12% in 2024 and then crashed by 3387.26% in 2025.
  • Quarter analysis of 3 years shows Immunome's Payables stood at $3.3 million in 2023, then soared by 328.54% to $14.2 million in 2024, then plummeted by 56.68% to $6.1 million in 2025.
  • Its Payables stands at $6.1 million for Q3 2025, versus $4.7 million for Q2 2025 and $9.1 million for Q1 2025.